Meta-AnalysisPubMed ID: 36281633·2022

Meta-Analysis: Tirzepatide and Weight Loss Outcomes

Sattar N, McGuire DK, Solomon SD, et al.

Obesity, 2022

Key finding

Tirzepatide doses 5-15mg achieved mean weight loss of 18.5-22.5% versus 2-6% placebo; superiority over GLP-1 agonists at 5-10%.

Summary

Systematic review and meta-analysis of tirzepatide trials across all phases demonstrating consistent weight loss superiority.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot